Find Your Funding Opportunity

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)
Bookmarked grants will display in your Account Setting page

Service Source Final Application Due Date Funding Available Match Required
Health Care Federal
HHS
07-01-2024 N/A No Match
Required
  • Service
  • Source
  • Final Application Due Date
  • Funding Available
  • Match Required
Status
  • Past
  • Current
  • Forecasted
    • Opportunity Type Discretionary
    • CFDA

      93.173 -- Research Related to Deafness and Communication Disorders

      93.233 -- National Center on Sleep Disorders Research

      93.395 -- Cancer Treatment Research

      93.837 -- Cardiovascular Diseases Research

      93.838 -- Lung Diseases Research

      93.839 -- Blood Diseases and Resources Research

      93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders

      93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research

      93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders

      93.865 -- Child Health and Human Development Extramural Research

      93.866 -- Aging Research

      93.867 -- Vision Research

    Description

    The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.

    Eligibility
    • IHE
    • Local Government
    • Non-Profit
    • Other
    • State Government
    • Tribal Government
    Additional Eligibility Information

    Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Key Date(s)
    • April 05, 2022: Last Updated Date
    • April 05, 2022: Posted Date
    • July 01, 2024: Current Closing Date for Applications
    • July 01, 2024: Application Due Date
    • August 06, 2024: Application Archive Date
    Contact Information

    NIH OER Webmaster

    OERWebmaster03@od.nih.gov

    DROP US A LINE

    Feedback Feedback

    Your opinion is important to us

    • How would you rate your overall experience on our website?

    • How easy is it to find the information you need?

    • How do you rate the look & feel of our website?

    • How could we improve our website?